卫光生物：公司非常重视市值管理，自上市以来持续通过现金分红、送红股等方式回报股东

Core Viewpoint - The company emphasizes its commitment to market value management and shareholder returns through various methods such as cash dividends and stock bonuses, while also enhancing its governance and information disclosure quality [2] Group 1: Shareholder Returns - The company has consistently implemented cash dividends and stock bonuses to reward all shareholders since its listing [2] - The company has achieved a "six consecutive A" rating in information disclosure from the Shenzhen Stock Exchange, reflecting its commitment to high governance standards [2] Group 2: Business Strategy - The company is focused on continuously improving its profitability and intrinsic value while solidifying its core business in blood products [2] - The company is actively expanding into cutting-edge fields such as cell and gene therapy in the biopharmaceutical sector to cultivate new profit growth points [2] - The company aims to enhance its competitive advantages through differentiation, thereby improving its long-term market value performance [2]